Concepedia

Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors

Thomas A. Hope, Emily K. Bergsland, Murat Fani Bozkurt, Michael M. Graham, Anthony P. Heaney, Ken Herrmann, James R. Howe, Matthew H. Kulke, Pamela L. Kunz, Josh Mailman,

Journal of Nuclear Medicine · 2017 · 351 citations · 66 references

DOIFull text

Open access

Concepts

Abstract

Somatostatin receptor (SSTR) PET has demonstrated a significant improvement over conventional imaging (CI) in patients with neuroendocrine tumors (NETs). SSTR PET should replace 111In-pentetreotide scintigraphy (OctreoScan; Mallinckrodt) in all indications in which the latter is currently being used

References

66

QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies

Penny Whiting · Annals of Internal Medicine · 2011 · 14K citations · Full text

, , +16

Grading quality of evidence and strength of recommendations

David C. Atkins, Dana Best, Peter A. Briss et al. · BMJ · 2004 · 8.5K citations · Full text

, , +10

Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews

Beverley Shea, Jeremy Grimshaw, George A. Wells et al. · BMC Medical Research Methodology · 2007 · 4.4K citations · Full text

, , +13

Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States

Arvind Dasari, Chan Shen, Daniel M. Halperin et al. · JAMA Oncology · 2017 · 3.5K citations · Full text

, , +17

Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors

Jonathan Strosberg, Ghassan El‐Haddad, Edward M. Wolin et al. · New England Journal of Medicine · 2017 · 3.2K citations · Full text

, , +17